INTRODUCTION

The coronavirus infection disease 2019 (COVID-19), the recent pandemic ravaging the world, is a serious health threat to mankind. Current research on COVID-19 vaccines shows that most of their known side effects are mild and self-limiting and do not require any specific treatment.1,2 However, some rare and partially recognized side effects of these vaccines may create serious life-threatening conditions. There are various types of atrioventricular (AV) conduction disorders. Second-degree type 2 AV block (mobitz II), including 2:1 AV block, results from the sudden failure of AV conduction without a progressive increase in the AV conduction time.3 In this case report, we presented a patient who developed 2:1 AV block a few days after being vaccinated for COVID-19.

CASE PRESENTATION

A 65-year-old man, without a noticeable health condition or history of serious diseases, was referred to the emergency department of our hospital (Shohada Hospital). His main complaints were dizziness and mild dyspnea. The patient's symptoms started a few days after receiving a COVID-19 vaccine (Sinopharm).

The patient's vital signs were as follows: blood pressure = 100/60 mmHg, respiratory rate = 15 breaths per minute, pulse rate = 37 beats per minute (bpm), oxygen saturation (room air) = 98%, and body temperature = 37°C. During lung clinical examination, auscultation was clear, and cardiovascular examination revealed no murmur. Laboratory investigations retrieved normal results (Table 1). The patient's electrocardiogram showed sinus rhythms with 2:1 AV-block and a narrow QRS complex. Coronary angiography showed mild coronary artery disease.

Abstract

A 65-year-old man became ill a few days after being vaccinated against the COVID-19 by the Sinopharm vaccine. Laboratory investigations, trans-thoracic echocardiography, and chest computed tomography scanning (CT-scan) retrieved normal results. The patient's electrocardiogram showed sinus rhythms with 2:1 AV-block and a narrow QRS complex. Coronary angiography showed mild coronary artery disease.

KEYWORDS

arrhythmia, AV block, SARS-CoV-2, vaccine
The patient underwent coronary angiography, which showed mild coronary artery disease without significant arterial stenosis (Figure 4). A temporary pacemaker (TPM) was inserted, and the patient was closely observed for several days afterwards, showing no AV block improvement. Therefore, a permanent pacemaker (PPM) was finally installed. After 1 week of admission to the hospital, the patient was discharged with a good general condition, and he was recommended to visit for the follow-up.

According to ethical guidelines, informed consent (in Persian, his national language) was obtained from the patient. Also, the patient was followed up for 1 month after admission, and he was recommended to visit every 6 months to check the performance of the PPM.

### 3 | DISCUSSION

Vaccination is regarded as the best preventive intervention against the COVID-19 infection and is believed to save millions of lives each year. Several brands of COVID-19 vaccines have been developed, including Sinopharm that works based on the virus inactivating technology and promotes immunity by introducing inactivated SARS-CoV-2 viruses into the body.

The most commonly reported side effects of this vaccine include headache, myalgia, and fever, which are generally mild and self-limiting with no requirement for treatment. Limited studies have reported an association between the COVID-19 infection and AV block. However, there are no reports suggesting an association between AV block and COVID-19 vaccines. In this study, we presented the case of a 65-year-old man who developed 2:1 AV block a few days after receiving a COVID-19 vaccine. The patient did not present extensive systemic, myocardial, or coronary involvement. There is little information on the cardiac complications of COVID-19 vaccines. Whether AV block development in our patient was secondary to an exaggerated inflammatory response or not remains unknown. Currently, there are limited guidelines on how to treat these patients. The American College of Cardiology (ACC) and American Heart Association (AHA) recommend cardiac pacemaker insertion for patients with second-degree AV block only if they present with symptomatic bradycardia, regardless of the site or type of the block. Considering the unpredictable course of second-degree AV block, a

| Parameters                  | Result | Normal range | Unit |
|-----------------------------|--------|--------------|------|
| White blood cell count      | 8      | 4.50–11      | 10 × 3/μl |
| Neutrophil count            | 45%    | 35–70        | %    |
| Lymphocyte count            | 25%    | 20–50        | %    |
| Red blood cell count        | 5.4    | 4.70–6.10    | 10 × 6/μl |
| Platelet count              | 251    | 150–450      | 10 × 3/μl |
| Hematocrit                  | 45.3   | 41–52        | %    |
| Hemoglobin                  | 14.5   | 12–16        | g/dl |
| Sodium                      | 138    | 135–145      | mmol/L |
| Potassium                   | 4.4    | 3.5–5.1      | mmol/L |
| Calcium                     | 9.1    | 9–10.5       | mg/dl |
| Magnesium                   | 2      | 1.3–2.1      | mEq/L |
| Creatinine                  | 0.95   | 0.5–1.20     | mg/dl |
| Blood urea nitrogen         | 27     | 12–45        | mg/dl |
| Glucose                     | 90     | 70–100       | mg/dl |
| D-dimer                     | 0.1    | 0–0.45       | µg/ml |
| C-reactive protein          | 0.6    | Less than 1.0| mg/dl |
| Troponin                    | 0.1    | 0–0.8        | ng/ml |
| Aspartate transaminase      | 39     | 17–60        | U/L  |
| Alanine aminotransferase    | 27     | 0–49         | U/L  |

**FIGURE 1** Findings of 12-lead electrocardiography in a patient receiving the first dose of the Sinopharm COVID-19 vaccine. The red arrow on the lead II shows the P wave with 2:1 AV block.
FIGURE 2 Patient’s lung CT-scan showed no pulmonary involvement.

FIGURE 3 No abnormality was observed in the transthoracic echocardiography of a patient presenting with 2:1 AV block after COVID-19 vaccination. (A) The supra-sternal view, (B) The apical four-chamber view, and (C) The parasternal short-axis view.

FIGURE 4 Patient’s coronary angiography results. The red arrow shows insignificant stenosis in the right coronary artery.

PPM was implanted for our patient based on a consensus decision-making.

In future studies, two issues should be addressed. First, the cardiac complications of COVID-19 vaccines should be more thoroughly evaluated to divulge the pathophysiology of the conduction disorders caused by these vaccines. Second, a suitable therapeutic method should be designed for the patients developing AV block after COVID-19 vaccination.

ACKNOWLEDGMENTS
Not applicable.

CONFLICT OF INTEREST
There is no conflict of interest.

AUTHOR CONTRIBUTIONS
EMN and SSA participated equally in case analysis and drafting the manuscript.
CONSENT
Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.

ORCID
Seyyed Shamsadin Athari © https://orcid.org/0000-0002-6355-6378

REFERENCES
1. Junapudi SS, Junapudi S, Ega K, Chidipi B. Major cardiac concerns in therapy and vaccinations for COVID-19. Metabol Open. 2021;11:100102.
2. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-226. doi:10.1016/j.ijid.2021.08.013
3. Damato AN, Jacob Varghese P, Caracta AR, Akhtar M, Lau SH. Functional 2:1 A-V block within the His-Purkinje system, simulation of type II second-degree A-V block. Circulation. 1973;47:534-542.
4. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192.
5. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354.
6. Azarkish M, Laleh V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J. 2020;41(22):2131.
7. Kir D, Mohan C, Sancassani R. Heart brake: an unusual cardiac manifestation of COVID-19. JACC Case Rep. 2020;2(9):1252-1255.
8. Mahdawi TE, Wang H, Haddadin FI, Al-Qaysi D, Wylie JV. Heart block in patients with coronavirus disease 2019: a case series of 3 patients infected with SARS-CoV-2. HeartRhythm Case Rep. 2020;6(9):652-656.
9. Al-assaf O, Mirza M, Musa A. Atypical presentation of COVID-19 as subclinical myocarditis with persistent high-degree atrioventricular block treated with pacemaker implant. HeartRhythm Case Rep. 2020;6(11):884-887.

How to cite this article: Mehrabi Nasab E, Athari SS. The first report of 2:1 atrioventricular block following COVID-19 vaccination. Clin Case Rep. 2022;10:e05797. doi:10.1002/ccr3.5797